I. Paul Singh, MD; and Nandini Venkateswaran, MD
Show Description +
Innovations in treatment of corneal disease affecting the front and back surface has lagged behind other areas of ophthalmology. That all may change soon. Nandini Venkateswaran, MD, gives a lowdown on recent studies looking at using engineered fibroblast growth factors (FGFs)—which are proven to improve healing while offering protective effects—in treatment of endothelial and epithelial cell defects affecting the cornea.
Posted: 8/31/2023
I. Paul Singh, MD; and Blake K. Williamson, MD, MPH, MS
I. Paul Singh, MD; and Charles C. Wykoff, MD, PhD, FACS
I. Paul Singh, MD; and Marguerite McDonald, MD, FACS
I. Paul Singh, MD; and Ranya Habash, MD
I. Paul Singh, MD; and J. Morgan Micheletti, MD
I. Paul Singh, MD; and Cathleen M. McCabe, MD
I. Paul Singh, MD; and Laura M. Periman, MD
I. Paul Singh, MD; and Leonard K. Seibold, MD
I. Paul Singh, MD; and Darrell E. White, MD
I. Paul Singh, MD; and Darrell E. White, MD
I. Paul Singh, MD; and Sila Bal, MD, MPH
I. Paul Singh, MD; and Arjan Hura, MD
I. Paul Singh, MD; and Dagny Zhu, MD
I. Paul Singh, MD; and Dagny Zhu, MD
I. Paul Singh, MD; and William F. Wiley, MD
I. Paul Singh, MD; and Steve Charles, MD, FACS, FICS
I. Paul Singh, MD; and Mark J. Gallardo, MD
I. Paul Singh, MD; and Ralph Chu, MD
I. Paul Singh, MD; and Mark Lobanoff, MD
I. Paul Singh, MD; and Sahar Bedrood, MD, PhD
I. Paul Singh, MD; and Brandon D. Ayres, MD
I. Paul Singh, MD; and Nathan M. Radcliffe, MD
I. Paul Singh, MD; and James A. Katz, MD
I. Paul Singh, MD; and Mark J. Gallardo, MD
I. Paul Singh, MD; and David S. Boyer, MD
I. Paul Singh, MD; and Douglas McGraw, DO
I. Paul Singh, MD; and Neel R. Desai, MD
I. Paul Singh, MD; and John P. Berdahl, MD
I. Paul Singh, MD
I. Paul Singh, MD; and Dagny Zhu, MD
I. Paul Singh, MD; and Zarmeena Vendal, MD
I. Paul Singh, MD; and Eric Donnenfeld, MD
I. Paul Singh, MD; and Christine M. Funke, MD
I. Paul Singh, MD; and Christine M. Funke, MD
I. Paul Singh, MD; and William F. Wiley, MD
I. Paul Singh, MD; and Marjan Farid, MD
I. Paul Singh, MD; and Cathleen M. McCabe, MD
I. Paul Singh, MD; and John Doane, MD
I. Paul Singh, MD; and Damien F. Goldberg, MD
I. Paul Singh, MD; and Darrell E. White, MD
I. Paul Singh, MD; and Denise M. Visco, MD, MBA
I. Paul Singh, MD; and Steven R. Sarkisian Jr, MD
I. Paul Singh, MD; and Carl D. Regillo, MD
I. Paul Singh, MD; and Carl D. Regillo, MD
I. Paul Singh, MD; and Julie Schallhorn, MD
I. Paul Singh, MD; and Sahar Bedrood, MD, PhD
I. Paul Singh, MD; and Jason Bacharach, MD
I. Paul Singh, MD; and Brandon D. Ayres, MD
I. Paul Singh, MD; and Arsham Sheybani, MD
I. Paul Singh, MD; and Robert J. Noecker, MD, MBA
I. Paul Singh, MD; and Mitchell A. Jackson, MD
I. Paul Singh, MD; and David Eichenbaum, MD
I. Paul Singh, MD; and Joe Panarelli, MD
I. Paul Singh, MD; and Gary Wörtz, MD
I. Paul Singh, MD; and Daniel S. Durrie, MD
I. Paul Singh, MD; and Karl G. Stonecipher, MD
I. Paul Singh, MD; and John A. Hovanesian, MD, FACS
I. Paul Singh, MD; and Christopher E. Starr, MD
I. Paul Singh, MD; and Nandini Venkateswaran, MD
Innovations in treatment of corneal disease affecting the front and back surface has lagged behind other areas of ophthalmology. That all may change soon. Nandini Venkateswaran, MD, gives a lowdown on recent studies looking at using engineered fibroblast growth factors (FGFs)—which are proven to improve healing while offering protective effects—in treatment of endothelial and epithelial cell defects affecting the cornea.
Posted: 8/31/2023
Ozana Moraru, MD
Alan Carlson, MD
Aaron T. Gomez, BS, Majid Moshirfar MD, Orry Birdsong, MD
Please log in to leave a comment.